Gosogliptin

Gosogliptin is a Dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) drug that was developed by Sanofi for the treatment of Type 2 diabetes. The drug was in Phase III clinical trials as of 2012, but development was discontinued.

Etymology[edit | edit source]

The name "Gosogliptin" is derived from the chemical name of the drug, which is (2S)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine.

Mechanism of Action[edit | edit source]

Gosogliptin, like other DPP-4 inhibitors, works by blocking the action of DPP-4, an enzyme which destroys the hormone Incretin. Incretins help the body produce more insulin only when it is needed and reduce the amount of glucose being produced by the liver when it is not needed. These actions lower blood glucose levels.

Development and Clinical Trials[edit | edit source]

Gosogliptin was developed by Sanofi, a French multinational pharmaceutical company. As of 2012, the drug was in Phase III clinical trials. However, development of the drug was discontinued for undisclosed reasons.

Related Terms[edit | edit source]

Gosogliptin Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.